Circulating microRNA signature for the diagnosis of very high-risk prostate cancer

Ali H. Alhasan, Alexander W. Scott, Jia J. Wu, Gang Feng, Joshua J. Meeks*, C. Shad Thaxton, Chad A. Mirkin

*Corresponding author for this work

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We report the identification of a molecular signature using the Scano-miR profiling platform based on the differential expression of circulating microRNAs (miRNA, miR) in serum samples specific to patients with very high-risk (VHR) prostate cancer (PCa). Five miRNA PCa biomarkers (miR-200c, miR-605, miR-135a∗, miR-433, and miR-106a) were identified as useful for differentiating indolent and aggressive forms of PCa. All patients with VHR PCa in the study had elevated serum levels of miR-200c. Circulating miR-433, which was differentially expressed in patients with VHR versus low-risk (LR) forms of PCa, was not detectable by quantitative real-time PCR in samples from healthy volunteers. In blind studies, the five miRNA PCa biomarkers were able to differentiate patients with VHR PCas from those with LR forms as well as healthy individuals with at least 89% accuracy. Biological pathway analysis showed the predictive capability of these miRNA biomarkers for the diagnosis and prognosis of VHR aggressive PCa.

Original languageEnglish (US)
Pages (from-to)10655-10660
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number38
DOIs
StatePublished - Sep 20 2016

Fingerprint

MicroRNAs
Prostatic Neoplasms
Tumor Biomarkers
Serum
Real-Time Polymerase Chain Reaction
Healthy Volunteers
Biomarkers

Keywords

  • Biomarker
  • Prostate cancer
  • Scano-miR
  • Spherical nucleic acid
  • microRNA

ASJC Scopus subject areas

  • General

Cite this

@article{362b91c334ec46fcb8ac150056355c25,
title = "Circulating microRNA signature for the diagnosis of very high-risk prostate cancer",
abstract = "We report the identification of a molecular signature using the Scano-miR profiling platform based on the differential expression of circulating microRNAs (miRNA, miR) in serum samples specific to patients with very high-risk (VHR) prostate cancer (PCa). Five miRNA PCa biomarkers (miR-200c, miR-605, miR-135a∗, miR-433, and miR-106a) were identified as useful for differentiating indolent and aggressive forms of PCa. All patients with VHR PCa in the study had elevated serum levels of miR-200c. Circulating miR-433, which was differentially expressed in patients with VHR versus low-risk (LR) forms of PCa, was not detectable by quantitative real-time PCR in samples from healthy volunteers. In blind studies, the five miRNA PCa biomarkers were able to differentiate patients with VHR PCas from those with LR forms as well as healthy individuals with at least 89{\%} accuracy. Biological pathway analysis showed the predictive capability of these miRNA biomarkers for the diagnosis and prognosis of VHR aggressive PCa.",
keywords = "Biomarker, Prostate cancer, Scano-miR, Spherical nucleic acid, microRNA",
author = "Alhasan, {Ali H.} and Scott, {Alexander W.} and Wu, {Jia J.} and Gang Feng and Meeks, {Joshua J.} and Thaxton, {C. Shad} and Mirkin, {Chad A.}",
year = "2016",
month = "9",
day = "20",
doi = "10.1073/pnas.1611596113",
language = "English (US)",
volume = "113",
pages = "10655--10660",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "38",

}

Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. / Alhasan, Ali H.; Scott, Alexander W.; Wu, Jia J.; Feng, Gang; Meeks, Joshua J.; Thaxton, C. Shad; Mirkin, Chad A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 38, 20.09.2016, p. 10655-10660.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Circulating microRNA signature for the diagnosis of very high-risk prostate cancer

AU - Alhasan, Ali H.

AU - Scott, Alexander W.

AU - Wu, Jia J.

AU - Feng, Gang

AU - Meeks, Joshua J.

AU - Thaxton, C. Shad

AU - Mirkin, Chad A.

PY - 2016/9/20

Y1 - 2016/9/20

N2 - We report the identification of a molecular signature using the Scano-miR profiling platform based on the differential expression of circulating microRNAs (miRNA, miR) in serum samples specific to patients with very high-risk (VHR) prostate cancer (PCa). Five miRNA PCa biomarkers (miR-200c, miR-605, miR-135a∗, miR-433, and miR-106a) were identified as useful for differentiating indolent and aggressive forms of PCa. All patients with VHR PCa in the study had elevated serum levels of miR-200c. Circulating miR-433, which was differentially expressed in patients with VHR versus low-risk (LR) forms of PCa, was not detectable by quantitative real-time PCR in samples from healthy volunteers. In blind studies, the five miRNA PCa biomarkers were able to differentiate patients with VHR PCas from those with LR forms as well as healthy individuals with at least 89% accuracy. Biological pathway analysis showed the predictive capability of these miRNA biomarkers for the diagnosis and prognosis of VHR aggressive PCa.

AB - We report the identification of a molecular signature using the Scano-miR profiling platform based on the differential expression of circulating microRNAs (miRNA, miR) in serum samples specific to patients with very high-risk (VHR) prostate cancer (PCa). Five miRNA PCa biomarkers (miR-200c, miR-605, miR-135a∗, miR-433, and miR-106a) were identified as useful for differentiating indolent and aggressive forms of PCa. All patients with VHR PCa in the study had elevated serum levels of miR-200c. Circulating miR-433, which was differentially expressed in patients with VHR versus low-risk (LR) forms of PCa, was not detectable by quantitative real-time PCR in samples from healthy volunteers. In blind studies, the five miRNA PCa biomarkers were able to differentiate patients with VHR PCas from those with LR forms as well as healthy individuals with at least 89% accuracy. Biological pathway analysis showed the predictive capability of these miRNA biomarkers for the diagnosis and prognosis of VHR aggressive PCa.

KW - Biomarker

KW - Prostate cancer

KW - Scano-miR

KW - Spherical nucleic acid

KW - microRNA

UR - http://www.scopus.com/inward/record.url?scp=84988672508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988672508&partnerID=8YFLogxK

U2 - 10.1073/pnas.1611596113

DO - 10.1073/pnas.1611596113

M3 - Article

C2 - 27601638

AN - SCOPUS:84988672508

VL - 113

SP - 10655

EP - 10660

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 38

ER -